2021
DOI: 10.3390/ijms22105213
|View full text |Cite
|
Sign up to set email alerts
|

Antitumor Activity of Nitazoxanide against Colon Cancers: Molecular Docking and Experimental Studies Based on Wnt/β-Catenin Signaling Inhibition

Abstract: In colon cancer, wingless (Wnt)/β-catenin signaling is frequently upregulated; however, the creation of a molecular therapeutic agent targeting this pathway is still under investigation. This research aimed to study how nitazoxanide can affect Wnt/β-catenin signaling in colon cancer cells (HCT-116) and a mouse colon cancer model. Our study included 2 experiments; the first was to test the cytotoxic activity of nitazoxanide in an in vitro study on a colon cancer cell line (HCT-116) versus normal colon cells (FH… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

1
8
0

Year Published

2022
2022
2025
2025

Publication Types

Select...
9

Relationship

1
8

Authors

Journals

citations
Cited by 18 publications
(9 citation statements)
references
References 55 publications
1
8
0
Order By: Relevance
“…Although our study is the first to demonstrate a therapeutic effect of NTZ on the bone metastasis of prostate cancer, its anticancer activity has been reported in recent studies in different types of cancers involving various molecular mechanisms. For example, it suppressed colon tumor growth likely by inducing cell cycle arrest and altering the expression of multiple molecules [52,53]; it suppressed ovarian cancer growth partially by inhibiting the protein disulfide isomerase (PDI) activity [54]; it inhibited sphere formation in 3D cultures of HCC and CRC cells involving the inhibition of OXPHOS [55,56]; and it suppressed glioma growth by causing the G2/M cell cycle arrest, inducing apoptosis, and inhibiting autophagy likely via CDK1 inhibition, ING1 upregulation, etc. [57,58].…”
Section: Discussionmentioning
confidence: 99%
“…Although our study is the first to demonstrate a therapeutic effect of NTZ on the bone metastasis of prostate cancer, its anticancer activity has been reported in recent studies in different types of cancers involving various molecular mechanisms. For example, it suppressed colon tumor growth likely by inducing cell cycle arrest and altering the expression of multiple molecules [52,53]; it suppressed ovarian cancer growth partially by inhibiting the protein disulfide isomerase (PDI) activity [54]; it inhibited sphere formation in 3D cultures of HCC and CRC cells involving the inhibition of OXPHOS [55,56]; and it suppressed glioma growth by causing the G2/M cell cycle arrest, inducing apoptosis, and inhibiting autophagy likely via CDK1 inhibition, ING1 upregulation, etc. [57,58].…”
Section: Discussionmentioning
confidence: 99%
“…Histologic scoring was used to determine the degree of dysplasia using previously stabilized parameters. In summary, tissue specimens were classified as having no dysplastic changes or having dysplastic changes: non-dysplasia—goblet cells that appear normal (basal-oriented nuclei and apical localization of mucus); mild dysplasia—hypercellularity of elongated cells and localized nuclear stratification were observed (hyperchromasia) [ 48 ].…”
Section: Methodsmentioning
confidence: 99%
“…Moreover, Qu et al reported that nitazoxanide also could suppress Wnt/β-catenin signaling through a specific target, PAD2, which is an enzyme responsible for protein citrullination, and thus induces citrullination of β-catenin [ 46 ]. Recently, a number of studies further reported that nitazoxanide downregulated the Wnt/β-catenin signaling pathway [ 48 , 130 , 131 ].…”
Section: Signaling Pathways Modulated By Salicylanilidesmentioning
confidence: 99%